Session » Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies

Meeting: 2014 ACR/ARHP Annual Meeting

Abstract Number: 1604

IFN-γ (Th₁), IL4 (Th₂), and IL5 (Th₂) Are Elevated in Pre-Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria

Abstract Number: 1605

Elevated Regulatory Mediators and Interferon Gamma Associated Responses, but Not Interferon Alpha, BLyS or IP-10, Accompany High-Titer Anti-Ro Autoantibodies in Asymptomatic Mothers of Children with Neonatal Lupus

Abstract Number: 1606

Profiling a Broad Range of Autoantibodies in Healthy and Systemic Lupus Erythematosis Revealed Autoantibody Patterns Associated with Autoantibody Transition and Disease Activity

Abstract Number: 1607

B Cell and Neutrophil-Related Transcripts Predict and Characterize a Lupus Flare

Abstract Number: 1608

Erythrocyte C4d and Antibodies to Anti-C1q Are Associated with Proteinuria in Lupus Nephritis

Abstract Number: 1609

Dissection of the Type I Interferon Response in Systemic Lupus Erythematosus : Serum IFNα Is Elevated in Lupus Nephritis and Correlates with IFN Score; IFNβ Is Elevated in Mucocutaneous Disease

Abstract Number: 1610

New Autoantigens Associated with Lupus Nephritis

Abstract Number: 1611

Modular Transcriptional Neutrophil Signature As Predictive of Nephritis and of Its Severity in SLE Patients

Abstract Number: 1612

Deficient Repair of DNA Double-Strand Breaks and Increased Apoptosis in Patients with Lupus Nephritis

Abstract Number: 1613

Circulating microRNAs As Candidate Biomarkers of Diagnosis in Systemic Lupus Erythematosus

Abstract Number: 1614

Functional Analysis of Interferon Responsiveness in PBMC from SLE Donors Identifies Subgroups with Higher and Lower Disease Activity

Abstract Number: 1615

MiR-127-3p As a Novel Regulator of Type I Interferon Signaling Pathway in SLE

Abstract Number: 1616

Functional Profiling of PBMC from SLE Patients Versus Healthy Controls Identifies Subgroups with Disease-Associated Dysfunctional Signaling

Abstract Number: 1617

Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes

Abstract Number: 1618

Suppression of IFN-α Production from Systemic Lupus Erythematosus Immune Complexes Via C1 Complex Enzymatic Properties

Abstract Number: 1619

Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs

Abstract Number: 1620

Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE)

Abstract Number: 1621

A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE

Abstract Number: 1622

Th1 and Th2 Cytokines Are Associated with Cerebral Atrophy in Systemic Lupus Erythematosus

Abstract Number: 1623

Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus

Abstract Number: 1624

The Role of B Lymphocyte Stimulator in Monocyte Subpopulation Differentiation in SLE

Abstract Number: 1625

Interferon Stimulates Transglutaminase Activity on Human Monocytes and Their Microparticles

Abstract Number: 1626

Autoantibodies Against High Mobility Group Box 1 (HMGB1) in Patients with SLE

« View all sessions from this meeting